New! Sign up for our free email newsletter.
Science News
from research organizations

Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity

Date:
April 2, 2011
Source:
American Association for Cancer Research
Summary:
The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to new data.
Share:

Story Source:

Materials provided by American Association for Cancer Research. Note: Content may be edited for style and length.


Cite This Page:

American Association for Cancer Research. "Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity." ScienceDaily. ScienceDaily, 2 April 2011. <www.sciencedaily.com/releases/2011/04/110402163403.htm>.
American Association for Cancer Research. (2011, April 2). Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity. ScienceDaily. Retrieved May 26, 2024 from www.sciencedaily.com/releases/2011/04/110402163403.htm
American Association for Cancer Research. "Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity." ScienceDaily. www.sciencedaily.com/releases/2011/04/110402163403.htm (accessed May 26, 2024).

Explore More

from ScienceDaily

RELATED STORIES